REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept

Stock News06-09 10:34

Shares of REMEGEN (HKEX: 09995) experienced a significant intraday rally, climbing more than 5% at one point during the trading session. As of the latest update, the stock was up 3.78%, trading at HK$71.3, with a turnover of HK$258 million.

The upward movement follows a major regulatory development. On June 8th, the company announced that its internally developed, first-in-class BLyS/APRIL dual-target fusion protein drug, Telitacicept (RC18), received approval from China's National Medical Products Administration (NMPA) for two new indications: Sjögren's Syndrome and IgA Nephropathy.

This approval marks a significant milestone, as Telitacicept becomes the first globally approved biologic for the treatment of Sjögren's Syndrome. Furthermore, it heralds a new era of precision therapy for IgA Nephropathy. With these latest approvals, Telitacicept now boasts a total of five approved indications in China, which also include Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Generalized Myasthenia Gravis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184903661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184903661","market":"sg","top_or_hot":-1,"title":"REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept","media":"Stock News","content":"<p>Shares of <b>REMEGEN</b> (<b>HKEX: 09995</b>) experienced a significant intraday rally, climbing more than 5% at one point during the trading session. As of the latest update, the stock was up 3.78%, trading at HK$71.3, with a turnover of HK$258 million.<br><br>\nThe upward movement follows a major regulatory development. On June 8th, the company announced that its internally developed, first-in-class BLyS/APRIL dual-target fusion protein drug, Telitacicept (RC18), received approval from China's National Medical Products Administration (NMPA) for two new indications: Sjögren's Syndrome and IgA Nephropathy.<br><br>\nThis approval marks a significant milestone, as Telitacicept becomes the first globally approved biologic for the treatment of Sjögren's Syndrome. Furthermore, it heralds a new era of precision therapy for IgA Nephropathy. With these latest approvals, Telitacicept now boasts a total of five approved indications in China, which also include Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Generalized Myasthenia Gravis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nREMEGEN Shares Surge on Dual Indication Approvals for Telitacicept\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-09 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>REMEGEN</b> (<b>HKEX: 09995</b>) experienced a significant intraday rally, climbing more than 5% at one point during the trading session. As of the latest update, the stock was up 3.78%, trading at HK$71.3, with a turnover of HK$258 million.<br><br>\nThe upward movement follows a major regulatory development. On June 8th, the company announced that its internally developed, first-in-class BLyS/APRIL dual-target fusion protein drug, Telitacicept (RC18), received approval from China's National Medical Products Administration (NMPA) for two new indications: Sjögren's Syndrome and IgA Nephropathy.<br><br>\nThis approval marks a significant milestone, as Telitacicept becomes the first globally approved biologic for the treatment of Sjögren's Syndrome. Furthermore, it heralds a new era of precision therapy for IgA Nephropathy. With these latest approvals, Telitacicept now boasts a total of five approved indications in China, which also include Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Generalized Myasthenia Gravis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1184903661","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184903661","pubTimestamp":1780972463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of REMEGEN (HKEX: 09995) experienced a significant intraday rally, climbing more than 5% at one point during the trading session. As of the latest update, the stock was up 3.78%, trading at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","09995":"荣昌生物","BK4585":"ETF&股票定投概念","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1574":"生物医药B类股","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0239":"医药制造","BK1583":"高瓴概念"},"translate_title":"REMEGEN股价因Telitacicept双重适应症获得批准而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1,"VXUS":1},"content_text":"Shares of REMEGEN (HKEX: 09995) experienced a significant intraday rally, climbing more than 5% at one point during the trading session. As of the latest update, the stock was up 3.78%, trading at HK$71.3, with a turnover of HK$258 million.\nThe upward movement follows a major regulatory development. On June 8th, the company announced that its internally developed, first-in-class BLyS/APRIL dual-target fusion protein drug, Telitacicept (RC18), received approval from China's National Medical Products Administration (NMPA) for two new indications: Sjögren's Syndrome and IgA Nephropathy.\nThis approval marks a significant milestone, as Telitacicept becomes the first globally approved biologic for the treatment of Sjögren's Syndrome. Furthermore, it heralds a new era of precision therapy for IgA Nephropathy. With these latest approvals, Telitacicept now boasts a total of five approved indications in China, which also include Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Generalized Myasthenia Gravis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184903661","isCrawlerRequest":true}